# Tigermed

> Tigermed is a VC fund in Hangzhou backing Biotechnology and Health Care. See 25 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Hangzhou, China
- Total investments: 25
- Last investment: Feb 2026
- Lead investor: 28%
- Last fund: Oct 2019
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/tigermed-consulting-ltd-/
- Website: http://www.tigermed.net

Tigermed is a contract research organization providing whole-process clinical trial services for the research and development of pharmaceutical products.

## Contacts

5 contacts available for Tigermed. Shizune tracks 2 team members at Tigermed. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/hangzhou-tigermed-technology-co-ltd?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 15 | 60% |
| Health Care | 14 | 56% |
| Pharmaceutical | 10 | 40% |
| Medical | 8 | 32% |
| Biopharma | 6 | 24% |

19 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 5 | 20% |
| Angel | 4 | 16% |
| Series A | 4 | 16% |
| Series B | 3 | 12% |
| Funding Round | 3 | 12% |

8 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| China | 20 | 80% |
| United States | 2 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Tianrong Ji | CIO | 25 | — |
| Xiaoping Ye | Founder&Chairman&CEO | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Tuosheng Pharmaceuticals | Tuosheng Pharmaceuticals is a biotechnology business that develops novel oncology medications and is dedicated to giving cancer patients breakthrough therapy choices. | $40M | Angel | Feb 03, 2026 |  |
| Bivision | Biovision Pharma is a biomedical enterprise focusing on the research and development of targeted radiopharmaceuticals (TRT) integrated with visual diagnosis and treatment. | $13.8M | Series A | Jul 26, 2024 |  |
| Suzhou Pelotin Biotechnology | Suzhou Pelotin Biotechnology is a research firm specializing in peptides, recombinant proteins, GE antibodies, and protein expression. | $1.4M | Seed | Jun 07, 2024 |  |
| Hipower | Hipower provides clinical trials and post-marketing clinical re-evaluation technical services for pharmaceutical products. |  | Series B | Oct 13, 2022 |  |
| LTZ Therapeutics | LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need. | $17M | Seed | Apr 07, 2022 |  |
| LTZ Therapeutics | LTZ develops novel immunotherapies to treat patients that suffer from cancer and other diseases with an unmet clinical need. | $17M | Seed | Apr 07, 2022 |  |
| BioInno | Beino Bio is a China-based supplier of biopharmaceutical CDMO and cell culture media, providing process development and GMP production services for companies interested in introducing protein, cell therapy and gene therapy drugs to the Chinese and global markets. |  | Series A | Dec 21, 2021 |  |
| Jisi Yingda | Jisi Yingda is a small-molecule anti-cancer drug developer, in the field of small-molecule tumor immune drugs and tumor drug development. |  | Series B | Nov 15, 2021 |  |
| CytoLynx Therapeutics | CytoLynx Therapeutics is a R&D and commercial platform leveraging Cytovia’s unique technologies and product pipeline. | $45M |  | Sep 13, 2021 |  |
| Adlai Nortye | Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates indevelopment. | $100M | Series D | Jul 13, 2021 |  |

10 of 25 investments shown.

## Co-investors
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 4 deals together
- [Yingke Capital](https://shizune.co/investors/profile/yingke-capital) — VC Fund, 3 deals together
- [BioTrack Capital](https://shizune.co/investors/profile/biotrack-capital) — VC Fund, 2 deals together
- [EFung Capital](https://shizune.co/investors/profile/efung-capital) — VC Fund, 2 deals together
- [K2 Global](https://shizune.co/investors/profile/k2-global) — VC Fund, 2 deals together
- [K2VC](https://shizune.co/investors/profile/k2-vc) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Tigermed invest in?

Tigermed invests primarily in Biotechnology, Health Care and Pharmaceutical startups, most often at Series C and Angel stage. Most of the 25 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Tigermed?

Public channels for Tigermed include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Tigermed?

The team at Tigermed includes Tianrong Ji (CIO) and Xiaoping Ye (Founder&Chairman&CEO). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co